Menu
Arquer Diagnostics is a UK based company that is developing a game-changing platform for a range of fast, non-invasive tests for diagnosing and monitoring cancer.
Our platform uses a patented technology built upon 20 years of research, to detect the presence of a protein produced by the expression of the MCM5 (Minichromosome Maintenance Complex Component 5) gene.
ADXBLADDER is the first of Arquer’s MCM5 tests to launch.
It is a CE marked in vitro diagnostic (CE IVD) bladder cancer test that can reduce the need for patients to undergo unnecessary, invasive and often painful testing, while helping to speed up the diagnosis of those at highest risk of having the disease.
Rigorous clinical trials involving approximately 3,000 patients show unequivocally that this innovative, non-invasive test is quicker and more accurate than the current standard diagnostic journey.
MCM protein biomarkers have been the subject of cancer research since they were first discovered at Cambridge University over 20 years ago by Prof. R Laskey and Prof. K Stoeber.
This protein biomarker discovery was used to develop the Arquer prototype MCM5 ELISA in collaboration with Cancer Research UK. That prototype has been perfected and extensively tested by the Arquer Team at its base in Sunderland (UK) and is undergoing clinical trials and further testing in a number of cancer types across the UK, Europe and the USA.
Arquer holds a number of patents relating to the technology.
Arquer’s technology platform is also showing positive early data in the diagnosis of prostate and endometrial cancers and similar products are undergoing clinical validations in these indications.
Our first study in endometrial cancer with ADXGYNAETM has recently been published.
“The very encouraging results of the first study are a great starting point for the clinical program we are engaging in. Should the results be confirmed, women will be able to access a new minimally invasive test for endometrial cancer diagnosis, decreasing the need for unnecessary invasive procedures”
Stockley J, Akhand R, Kennedy A, Nyberg C, Crosbie EJ, Edmondson RJ. Detection of MCM5 as a novel non-invasive aid for the diagnosis of endometrial and ovarian tumours. BMC Cancer. 2020 Oct 15;20(1):1000. PMID: 33059604; PMCID: PMC7559715.
Link: 10.1186/s12885-020-07468-y
NHS Urologists: To discuss how to get ADXBLADDER testing in a NHS Hospital, please contact ArquerDX directly on 0191 516 6765.
